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INTRODUCTION 
 
Frailty is a clinically recognizable state of increased 
vulnerability to stressor events resulting from the 
systemic decline in function and physiological reserve 
mechanisms with aging [1]. This weakening condition  
 
detrimentally affects the normal physical activity and 
is associated with an increased risk for adverse 
clinical outcomes and death [2]. Therefore, frailty 
reflects the individual’s biological age and life 
expectancy better than chronological age [3]. Studies 
in long-living individuals (LLIs), which, in spite of 
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ABSTRACT 
 
Background: There is an increasing concern about age-related frailty because of the growing number of elderly 
people in the general population. The Longevity-Associated Variant (LAV) of the human BPIFB4 gene was found 
to correct endothelial dysfunction, one of the mechanisms underlying frailty, in aging mice whereas the  
RV-BPIFB4 variant induced opposite effects. Thus, we newly hypothesize that, besides being associated with life 
expectancy, BPIFB4 polymorphisms can predict frailty. 
Aim and Results: Here we investigated if the BPIFB4 haplotypes, LAV, wild-type (WT) and RV, differentially 
associate with frailty in a cohort of 237 elderly subjects from Calabria region in Southern Italy. Moreover, we 
studied the effect of systemic adeno-associated viral vector-mediated LAV-BPIFB4 gene transfer on the 
progression of frailty in aging mice. We found an inverse correlation of the homozygous LAV-BPIFB4 haplotype 
with frailty in elderly subjects. Conversely, carriers of the RV-BPIFB4 haplotype showed an increase in the frailty 
status and risk of death. Moreover, in old mice, LAV-BPIFB4 gene transfer delayed frailty progression.  
Conclusions: These data indicate that specific BPIFB4 haplotypes could represent useful genetic markers of 
frailty. In addition, horizontal transfer of a healthy gene variant can attenuate frailty in aging organisms. 
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their exceptional biological age, are protected from and 
cope better with age-related diseases, confirm this 
concept [4]. Moreover, several genetic factors that are 
reportedly implicated in the determination of 
exceptional longevity are also inversely related with 
frailty disabilities [5, 6]. 
 
The Bactericidal/Permeability-Increasing Fold-Containing 
Family B member 4 (BPIFB4) gene encodes a secreted 
protein, initially found to be expressed in salivary 
glands, and more recently discovered to play important 
pathophysiological roles at systemic level. A genome 
wide association study (GWAS), performed on an 
Italian set of LLIs and controls and validated on two 
independent populations from Germany and USA, 
identified the BPIFB4 variants associate with lifespan 
[7]. We found a consistent enrichment of the minor 
allele of the nonsynonymous single nucleotide 
polymorphism (SNP) rs2070325 of BPIFB4 (identifier: 
P59827.2), under recessive model, in LLIs. The 
rs2070325 is part of a four SNPs haplotype that codifies 
for a wild type variant (WT), a longevity-associated 
variant (LAV) and a rare variant (RV) of BPIFB4, 
represented respectively by the 66%, the 29.5% and the 
4% of the alleles [7]. In more detail, the rs2070325 
variation (Ile229Val) of BPIFB4 is in perfect linkage 
disequilibrium with rs2889732 (Asn281Thr), while both 
show a limited amount of recombination events with 
rs11699009 (Leu488Phe) and rs11696307 (Ile494Thr). 
Thus, the main three alternative haplotypes are WT 
(Ile229/Asn281/Leu488/Ile494-BPIFB4 isoform), LAV 
Val229/Thr281/Phe488/Thr494-BPIFB4 isoform), and 
RV (Ile229/Asn281/Phe488/Thr494-BPIFB4 isoform) 
that carries the major alleles of rs2070325 and of 
rs2889732 and the minor allele of rs11699009 and 
rs11696307. 
 
The BPIFB4 protein is expressed in undifferentiated and 
highly proliferative cells and in fetal/stressed heart tissue 
(cardiac hypertrophy), which share a common hypoxic 
environment. Overexpression of BPIFB4 isoforms 
induced the activation of stress response-related heat-
shock proteins (HSPs) and the modification of protein 
homeostatic processes (translation, ribosome biogenesis, 
spliceosome), two processes that are usually lost during 
aging. Furthermore, the circulating levels of 
immunoreactive BPIFB4 protein are reportedly higher in 
healthy LLIs than in diseased LLIs or young controls [8]. 
Similarly, CD34+ hematopoietic cells and mononuclear 
cells (MNCs) of LLIs expressed higher levels of BPIFB4 
than corresponding cells of young controls [8, 9]. Studies 
in experimental models of cardiovascular disease 
confirmed that overexpression of the human LAV- 
BPIFB4 gene results in attenuation of hypertension, 
atherosclerosis, and ischemic disease, which are 
hallmarks of aging [4]. 
The aim of the present study was to investigate the 
novel hypothesis that BPIFB4 haplotypes segregate 
with frailty, which was assessed using a methodology 
specifically developed for the geographical location of 
the study [10]. We challenged this hypothesis in a 
cohort of elderly subjects with an age comprised 
between 65-90 years, a life period where frailty is 
acknowledged to increase progressively in humans [2]. 
In addition, to obtain direct functional evidence for this 
association, we attempted to combat frailty in old mice 
using gene therapy with LAV-BPIFB4. Among various 
assessment tools for frailty in mice [11–14], we have 
chosen to use an index that calculate the accumulation 
of deficits [14] and we also validated the results 
considering treatment outcomes in a combined model 
comprising physical frailty [11] and mortality. Results 
of this research highlight the predictive value and 
therapeutic potential of LAV-BPIFB4 in age-related 
frailty. 
 
RESULTS 
 
Association with frailty and survival in humans 
 
The baseline characteristics of the cohort are illustrated in 
Table 1. The association analyses with frailty trait showed 
that the LAV homozygous haplotype is under-represented 
in frail subsets of the cohort (p = 0.030 vs. other 
haplotypes), thus suggesting a potentially protective role 
of this variant (Table 2 and Figure 1). Conversely, carriers 
of the RV haplotype are more frequently frail (p = 0.031 
vs. other haplotypes), whereas the WT haplotype did not 
allow to distinguish between frail and not frail subjects 
(Table 2 and Figure 1).  
 
Looking at the variants influence on lifespan, we 
analyzed the survival of RV and LAV carriers using a 
Cox regression. We could see a negative effect on 
survival by the RV haplotype (adjusted HR = 4.066; p = 
0.044) but not by the LAV haplotype (adjusted HR = 
0.002; p = 0.97) (Figure 2). Likewise, the WT haplotype 
was uninfluential (data not shown).  
 
Effect of gene therapy with AAV-LAV-BPIFB4 on 
frailty in aging mice 
 
Systemic gene therapy with LAV-BPIFB4 resulted in a 
slight but significant delay in the progression of clinical 
frailty. In fact, mice injected with LAV-BPIFB4 
displayed a significant lower frailty index at 7-month 
follow-up (2 months after the last injection of the gene) 
as compared with controls (Figure 3A). A subgroup 
analysis by age groups revealed that only old mice, but 
not adult mice, treated with LAV-BPIFB4 had a lower 
frailty index from 5- to 7-month follow-up compared 
with age-matched controls (Figure 3B). On the other 
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Table 1. General characteristic of the analyzed groups at the time of the recruitment. 
Calabria cohort (N= 237) 
Mean Age (SD) 73.4 (6.2) 
Age Range 65–90 
Female, N (%) 131(55.3) 
Non-Frail, N (%) 121 (51.0) 
Frail, N (%) 116 (49.0) 
 
Table 2. Distribution of BPIFB4 haplotypes in Calabria population stratified by frailty levels. 
Haplotype Models Non frail N (%) 
Frail 
N (%) p-value* 
LAV Homo Carriers/Others 
13 (10.7) 
108 (89.3) 
4 (3.4) 
112 (96.6) 
 
0.030 
RV Carriers Others 
7 (5.8) 
114 (94.2) 
16 (13.8) 
100 (86.2) 
 
0.031 
WT Homo Carriers/ Others 
53 (43.8) 
68 (56.2) 
48 (41.4) 
68 (58.6) 
 
0.403 
*p-value assessed by Fisher’s Exact test. 
 
hand, an analysis based on the prevalence of physical 
frailty could not capture a significant effect of LAV-
BPIFB4 gene therapy in old mice at the 7-month 
assessment (20.0 vs. 44.4% in controls, p = 0.170 by 
Fisher’s exact test, Supplementary Table 1).  
 
From the time of the first injection (3rd month) up to the 
12th month assessment, we recorded 24 deaths in 
controls and 22 deaths in the LAV-BPIFB4-treated 
group within the old cohort, while the deaths in the 
adult cohort were 10 and 11, respectively. We found no 
significant difference in the mortality hazard between 
the treatment and control groups at the 12th month, 
either considering the whole population (control vs. 
treatment group HR = 1.33, CI = 0.75-2.34; p = 0.33) or 
the old sub-population (control vs. treatment group  
HR = 1.28, CI = 0.68-2.41; p = 0.43). 
We deemed that any further follow-up for survival after 
the 12th month would have been unnecessary as the 
colony of old mice was numerically exhausted. We also 
argued that the excess death from the 7-month assessment 
onwards could had invalidated the power of the physical 
frailty analysis. Since part of these deaths in the old group 
may have arisen as an outcome of frailty, we also 
compared the combined prevalence of physical frailty and 
deaths in the treated and control mice. Accordingly, the 
prevalence of this combination was significantly lower in 
LAV-BPIFB4-treated old mice as compared with control 
mice (28.6 and 61.5%, respectively, p = 0.03 by Fisher’s 
exact test, Table 3). Interestingly, the proportion of old 
mice with reduced grip strength and gait disorders, which 
are parameters of the clinical frailty index related to the 
physical phenotype, were improved at the 7th month by 
LAV-BPIFB4 (Supplementary Table 2). 
 
 
 
Figure 1. Distribution of RV carriers, LAV Homozygous and WT Homozygous subjects across the groups defined by cluster 
analysis. 
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Figure 2. Survival function of: (A) LAV Homozygous carriers and (B) RV carriers (solid line) vs others (dotted line) in the Calabria cohort. Time 
is expressed in months, where 0 is considered the time of recruitment, and each individual is followed up for survival status till death. 
Adjusted HR and p-values are reported inside the Figure.  
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DISCUSSION 
 
Frailty is a common clinical syndrome of functional 
decline related to aging characterized by marked 
vulnerability. Its distinctive phenotype can be 
categorized on physical attributes, such as stamina, 
strength, speed, activity and weight, [15] or as a deficit 
model, in which the risk of adverse events accumulates 
due to the impairment in several psychophysical 
domains [16]. The latter definition appears to be better 
suited to predict mortality both in humans [17] and mice 
[18] but there is no current consensus about frailty 
assessment tool that should be used. 
 
There is a remarkable heterogeneity for frailty in 
different geographic areas. Therefore, we used a frailty 
index tool that was previously employed in the same 
region of our study to foresee the health status and 
perspective survival of a geriatric population with an 
age range of 65–108 years [10]. This classification was 
replicated in two large longitudinal Danish samples, 
which confirmed the predictive soundness after 10-
years of follow up [19]. The analysis revealed a 
significant underrepresentation of frailty in old 
individuals of the homozygous LAV-BPIFB4 haplotype. 
Moreover, we observed a reduced survival rate in RV 
carriers during 10-years follow-up as compared with the 
carriers of the LAV and WT haplotypes.  
 
To validate the cause-effect value of the gain-of-
function mutation, we delivered the human LAV-
BPIFB4 gene to adult or old mice via a viral vector. 
Interestingly, in old mice, gene therapy attenuated the 
progression of clinical frailty, whereas the treatment 
was not effective on physical frailty. Mice develop 
physical disability only at the extreme stage of life, as 
seen in longitudinal screening investigations [20]. 
Therefore, one possible explanation for the lack of 
physical benefit by LAV gene therapy is that there was 
little room for improvement at the age studied here. 
Moreover, the physical frailty phenotype not only 
underlies a different form of vulnerability compared 
with clinical frailty, but also requires larger sample 
sizes. Considering the number of mice lost to follow-up 
due to premature death, the assessment on physical 
frailty at 7th months might not have enough power to 
reject the null hypothesis. To mitigate this limitation, 
we considered the effect of gene therapy on the 
combined outcomes of physical frailty and death events. 
Using this approach, we found a significant improve-
ment in LAV-treated animals compared with age-
 
 
 
Figure 3. Effect of AAV-LAV-BPIFB4 on the clinical frailty index [FI (31 items)] in mice. FI was monitored each month from the 
inclusion (1st month) up to the 7th month. Injection of AAV-LAV-BPIFB4 (treatment group; solid line) or AAV-GFP (control group; dotted 
line) was performed at the 3rd and 5th month. (A) FI changes during the study in the whole cohort of mice; (B) FI changes during the study 
in the cohort of mice subdivided on the basis of the age at inclusion in adult (age range 16-17 months) and old mice (age range 18-23 
months). Values of FI are means ± SEM. Statistics to compare FI between treatment and control group was performed using mixed model 
analysis for longitudinal data (SPSS v. 24.0) including time, treatment, age group and gender as fixed factors and age of mice at the 
inclusion as covariate; *P<0.05; **P<0.01. BPIFB4 indicates bactericidal/permeability-increasing fold-containing-family-B-member-4; GFP, 
green fluorescent protein; and LAV, longevity-associated variant. 
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Table 3. Prevalence of combined physical frailty and deaths1 in treated and control mice at the 3rd month (before 
treatment) and at the 7th month (after treatment) from the inclusion in the study*. 
Age of mice at the 
beginning of the 
study 
Status 
Month 3 
(Before treatment) 
Month 7 
(Post treatment) 
Control LAV-BPIFB4 Control LAV-BPIFB4 
Adult mice Frail + deaths 2 (8.3%) 1 (4.5%) 5 (20.8%) 2 (9.1%) Non-frail 22 (91.7%) 21 (95.5%) 19 (79.2%) 20 (90.9%) 
Old mice Frail + deaths 4 (15.4%) 3 (10.7%) 16 (61.5%) 8 (28.6%) Non-frail 22 (84.6%) 25 (89.3%) 10 (38.5%) 20 (71.4%) 
1 Death-events included in the outcome consists of all mice dying from month 3 up to month 7.  
* Data are reported as number of mice (%). For adult mice all comparisons between treated and control groups were not 
significant (p > 0.05). For old mice at month 3, p = 0.741 by Fisher’s exact test; For old mice at month 7, p = 0.03 by Fisher’s 
exact test. 
 
matched controls. Hence, the data support a protective 
role of the gene therapy in the onset of clinical and 
physical frailty in old rodents. 
 
Observational studies have linked endothelial dys-
function with frailty, thus supporting the concept that 
poor circulation could compromise the whole body 
homeostasis and thereby the ability of an old organism 
to cope with stress [21, 22]. Previous studies of BPIFB4 
gene transfer in elderly mice demonstrated the LAV 
exerts benefits on endothelial function, while RV is 
detrimental. This dichotomy corresponded to 
consensual changes in eNOS activity, which was 
increased by LAV and reduced by RV [9, 23]. Therefore, 
one possible interpretation of the new data presented 
here is that LAV can halt frailty by protecting the 
vasculature from aging and aging-related risk factors, 
whereas RV causes the contrary. 
 
Both atherosclerosis and inflammatory processes have 
been considered as central hubs for frailty [24, 25]. A 
systematic review and meta-analysis suggested that 
frailty and pre-frailty are associated with higher 
inflammatory parameters [26]. We recently showed that 
LAV-BPIFB4 gene therapy counteracted the 
development of vascular atherosclerosis in ApoE 
knockout mice fed a high fat diet [27]. Moreover, LAV-
BPIFB4 protein induced M2 monocytes polarization 
and exerted anti-inflammatory effects [28]. Therefore, it 
is tempting to speculate that LAV-BPIFB4 may have 
contrasted the low-grade chronic inflammation that is 
typical of progressive atherosclerotic disease. 
 
The association of the LAV haplotype with lower frailty 
in elderly subjects and the reduced frailty observed in 
mice treated with LAV-BPIFB4 gene therapy are in 
perfect agreement. However, in both cases (human and 
mice), there was no impact of LAV on survival. In the 
human study, however, the RV haplotype was 
associated with a worse survival. This is not the first 
case where interventions influencing health span do not 
benefit lifespan. There are, indeed, evidence from 
studies in animal models showing that genetic or other 
types of intervention, such as life-long spontaneous 
exercise [29] and supplementation with nicotinamide 
[30], improve aspects of healthy aging, without 
concomitantly increasing lifespan. This might occur, for 
instance, if an intervention modulates age-dependent 
disorders that are cause of disability and morbidity but 
are not the principal causes of mortality. Likewise, 
tissue-specific effects of genetic variations might 
improve the effects of aging in an organ without 
improving survival. In addition, the lack of association 
of the LAV haplotype with survival in the human cohort 
may be attributed to a lower penetrance on this trait. 
Therefore, the follow-up time of 10 years on a small 
population may not be long enough to detect variations 
in the risk of death. This would not be the case for the 
RV haplotype, which is rarest but likely more penetrant 
on the survival phenotype. The enrichment of the LAV 
haplotype we have previously reported in LLIs could be 
indeed the result of a higher mortality of RV carriers. 
 
Study limitations 
 
Although genetic and molecular evidences support the 
role of BPIFB4 haplotypes in aging and longevity, 
additional studies should be carried out to confirm their 
role in the susceptibility to frailty. Due to the specificity 
of the studied cohort, replication in different and larger 
populations should be performed. Furthermore, an 
evaluation for a longer time is necessary to definitively 
determine the impact of the LAV haplotype on the risk 
of death. Likewise, larger cohorts of mice would be 
necessary to provide enough power in the assessment of 
survival. 
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CONCLUSIONS 
 
To the best of our knowledge, this is the first study 
presenting both associative clinical evidence and 
experimental proof of concept for a gene’s haplotypes 
to influence frailty. These data could have important 
clinic and therapeutic implications. Screening the 
BPIFB4 haplotypes could provide important 
information on the individual’s risk to develop 
disability with aging and thus help clinicians in 
elaborating precision medicine decisions. This and 
similar genome-based technologies could shift the 
treatment (and associated costs) from acute intervention 
and disease management to an effort in assessing health 
and proactive control of disease risks and prevention. 
Furthermore, preclinical data on BPIFB4 gene therapy 
provide a further scope for the horizontal transfer of the 
healthy features of centenarians to individuals at risk. 
Clinical studies confirming safety and efficacy of such 
therapy could pave the way to new treatment capable of 
improving general health and reducing care costs 
dramatically.  
 
METHODS 
 
Human sample description 
 
The Calabria cohort involved in this study is a subset of 
a larger population already described by Montesanto  
et al. [10]. This subset includes a total of 237 unrelated 
individuals (106 men and 131 women) 65–90 years old 
(median age 72 years), participated in the present study. 
All the subjects lived in Calabria (southern Italy) and 
their origin in the area have been verified up to the 
grandparent’s generation, as previously described [10]. 
Health status was ascertained by medical visit carried 
out by a geriatrician through a structured interview 
including physical and cognitive tests, as well as 
questions on common diseases occurred in the past. At 
the same time, it was performed DNA extraction and 
hematological analyses on peripheral venous blood 
samples. 
 
For analyzing the correlation with quality of aging of 
the genetic variants investigated, we used the frailty 
classification of this sample, as obtained in a previous 
work [10]. In brief, according to this approach, each 
individual can be classified respect to his/her frailty 
level, determined by applying a hierarchical cluster 
analysis (HCA) on specific geriatric parameters, 
including Mini Mental State Examination (MMSE), 
Self-Reported Health Status (SHRS), Activity of Daily 
Living (ADL) and Hand Grip (HG) strength. For this 
population, two clusters were considered: non frail (the 
cluster with subjects showing the best scores for the 
classification variables) and frail (the clusters with 
subjects showing the worst scores for the classification 
variables). Furthermore, Calabria cohort has been 
followed-up for 10 years.  
 
Ethics statement 
 
Investigation has been conducted in accordance with the 
ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors' 
institutional review board. Each subject, before the visit, 
signed an informed consent, for the permission to 
collect blood samples and usage of register-based 
information for research purposes 
 
Genotyping  
 
Samples were genotyped using Taqman assays for 
SNPs rs2070325 and rs11699009, to identify 
haplotypes. Alleles of rs2889732 and rs11696307 were 
imputed, given that are in total LD with the previous 
named respectively. It was performed data analysis with 
QuantStudio software 1.1 (ThermoFisher Scientific). 
 
Gene therapy with AAV-LAV-BPIFB4 in mice  
 
Constructs and vectors used in this study 
We used LAV-BPIFB4- and green fluorescent protein–
encoding adeno-associated viral vectors (AAV serotype 
9 with a TBG promoter) to transduce mice. Details on 
the construction of these constructs have been 
previously described [9].  
 
Animal study 
All experiments were performed according to the 
European Community Council Directives of 2010/63/UE 
and the protocol was approved according to current Italian 
law (D.Lgs. n. 26/2014) by the General Direction of 
Animal Health and Veterinary Drugs of the Italian 
Ministry of Health with the authorization n° 130/2018-
PR. We used C57BL/6J mice housed under specific 
pathogen-free (SPF) conditions in a room with controlled 
temperature (22 ± 2°C) and a 12-h light–dark cycle, with 
ad libitum access to food and water.  
 
A total of 103 mice (71 males and 32 females) were 
used in the study. Three mice died before any treatment 
was performed and were excluded from the study. The 
mice were assigned to two age-matched experimental 
groups: a treatment group (AAV-LAV-BPIFB4;  
50 mice) and a control group (AAV-GFP; 50 mice). The 
experimental groups were further subdivided into 4 
subgroups based on the age of the mice at the start of 
the study. The first group consisted of “adult controls” 
(24 mice, 11 females and 13 males) aged 16-17 months 
(mean age ± SD = 16.8 ± 0.7 months). The second 
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group consisted of “treated adults” (22 mice, 9 females 
and 13 males) aged 16-17 months (mean age ± SD = 
16.7 ± 0.7 months). The third group consisted of “old 
controls” (26 mice, 4 females and 22 males) aged 18-23 
months (mean age ± SD = 21.6 ± 1.9 months). The 
fourth group consisted of “treated old” (28 mice,  
8 females and 20 males) aged 18-23 months (mean age 
± SD = 21.0 ± 2.0 months). We performed non-invasive 
measurements of clinical frailty once a month in all 
mice. Physical frailty data were recorded at the 3rd and 
at the 7th month from the start of the study. After 
recording the frailty data at the 3rd month, we injected 
(i.v.) into the tail vein 1*1014 viral particles of AAV-
LAV-BPIFB4 or AAV-GFP in the treatment and control 
groups, respectively. The same treatment was repeated 
at the 5th month from the start of the study. We also 
recorded the time to death for each mouse until the  
12th month since the beginning of the experiment. 
Mortality occurred when animals died suddenly or 
euthanized due to illness. A detailed design of the study 
is reported in Supplementary Figure 1. 
 
Measurement of frailty in mice  
 
We measured both clinical and physical frailty in mice. 
We measured the clinical frailty index (FI) in mice 
based on the validated murine clinical FI tool described 
previously [14]. Details on the measurement of weight, 
body surface temperature and grip strength (which are 
included in the FI tool) have been also described 
previously [12]. FI data were recorded the second week 
of each month from 10 am to 2 pm. All measurements 
of frailty were performed within the SPF animal facility 
of INRCA in a dedicated area. The clinical FI score for 
each mouse was calculated using the checklist 
published previously [14]. Clinical assessment included 
evaluation of the integument, musculoskeletal system, 
vestibulocochlear and auditory systems, ocular and 
nasal systems, digestive system, urogenital system, 
respiratory system, signs of discomfort, as well as the 
body weight and body surface temperature. For each 
parameter, a score of 0 was given if there was no sign of 
a deficit, a score of 0.5 denoted a mild deficit and a 
score of 1 indicated a severe deficit. Deficits in body 
weight and body surface temperature were scored based 
on their deviation from average reference values 
obtained from the entire cohort. Values that differed 
from reference values by less than 1 SD were scored as 
0. Values that were ±1 SD with respect to the reference 
value were given a frailty value of 0.25; values that 
differed by ±2 SD scored 0.5, those that differed by  
±3 SD scored 0.75 and values that were >3 SD above or 
below the mean received the maximal frailty value of 1. 
The sum retrieved from the values assigned to the 31 
items on the checklist was then divided by 31 to yield a 
FI score between 0 and 1 for each animal. 
The measurement of physical frailty in mice was 
performed following the same procedure described to 
translate the physical frailty screening performed in 
humans [1] to mice [11, 20, 31]. Performance testing 
was performed in both old and adult mice at the 3rd 
month from the start of the study (before the treatment 
period) and at the 7th month (after the treatment period). 
In order to ensure testing reliability, we adapted the 
mice to the tests for at least 2 months before the start of 
the study and performed multiple measurements for 
each criterion of the frailty assessment. The results from 
the multiple measurement were combined in a unique 
score for each criterion. The same testers performed all 
the measurements of frailty. All measurements 
performed to define the Physical Frailty phenotype are 
schematically described in Supplementary Table 3. 
 
Our frailty phenotype included the following physical 
components:  
 
1. Shrinking (weight loss). Shrinking was assessed by 
recording the current body weight and changes of body 
weight (these last measurements were obtained by 
comparing the current weight with the one measured in 
the previous 1 and 2 months). 
 
2. Weakness. This criterion was assessed by measuring 
forelimb grip strength with 3 different tests: grip 
strength meter (Ugo Basile, Varese, Italy) measurement 
[32], dynamometer force measurement and increasing 
weights lift test [33]. 
 
3. Endurance. This criterion was measured by treadmill 
distance (program: starting at 5 rpm for 2 min and 
increasing speed from 5 to 50 m/s in 2700 s), mean time 
to fall at rotarod test (program: starting at 5 m/s for  
2 min and increasing speed from 5 to 40 rpm in 300 s) 
and max weight reached at the increasing weights lift 
test. This test includes an endurance component due to 
the continuous increasing of the weight to be lifted by 
the mouse [33]. 
 
4. Slowness. We assessed this criterion by analyzing the 
distribution of the time spent by the mouse in different 
speed intervals in an Open Field test (whole test duration 
5 min). The speed intervals considered where: I1 (0-1 
cm/s), I2 (1-5 cm/s), I3 (5-10 cm/s), I4 (10-15 cm/s), I5 
(15-20 cm/s), I6 (20-25 cm/s), I7 (25-30 cm/s), I8 (30-35 
cm/s), I9 (35-40 cm/s), I10 (40-90 cm/s). We recorded the 
highest speed interval that the mouse run for at least 3 s 
and assigned as value of the test the mean speed of the 
interval (e.g. 12.5 for I4 and 37.5 cm/s for I9). The 
threshold of 3 s was established based on association with 
mortality data obtained from other cohort of mice (data 
not shown). Locomotor activity was conducted by a 5-min 
open field test on a white wood-chamber (72×72×30 cm) 
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surmounted by a Xiaomi Yi Camera 16MP 1080 P 60FPS 
(YI Technology) controlled WI-Fi by a Smartphone. 
Videos were collected in a microSD disk and the tracking 
was performed offline with Biobserve Viewer3 
(Biobserve GmbH, Germany) as previously described 
[12]. An additional measurement for slowness was 
obtained by recording the max speed recorded at rotarod 
test. Furthermore, we assessed slowness by also including 
the measurement of the mean stride length of the mice 
following a previously established protocol [34]. Indeed, 
there is a strong rationale in support of the relationship 
between walking speed and stride length, especially in 
older individuals [35]. 
 
5. Activity. Activity was recorded automatically by 
Biobserve Viewer3 (Biobserve GmbH, Germany) as the 
% the mice walked or run (speed above 0.45 cm/s) in a 
5-min open field test. We additionally recorded the total 
distance run by the mouse in the same test. 
 
All variables obtained by the measurements described 
above were standardized (transformed into Z-scores) 
and the variables assigned to the same criterion  
were averaged to create a composite Z-score. Following 
the percentiles used by Fried et al. in humans [1] and by 
others in mice [20], mice that fell in the bottom 20% of 
our old cohort for the composite Z-score computed for 
each criterion (Shrinking, Weakness, Endurance, 
Slowness and Activity), were considered positive for 
frailty for that given criterion. Mice with three or more 
positive frailty criteria were identified as frail. 
 
Statistical analysis  
 
Human study  
For all the analyses, we re-codified the classification at 
BPIFB4 locus taking into account the haplotypic phase, 
as previously reported [23]. Since the LAV is 
represented by the minor allele of the two SNPs in 
haplotypic phase, the association with frailty trait was 
tested assuming a recessive model for this allele (i.e., 
LAV homozygotes – defined as rs2070325 = G and 
rs11699009 = T on both chromosomes – vs. LAV 
heterozygotes – defined as rs2070325 = G and 
rs11699009 = T on one chromosome – plus remaining 
haplotype carriers pooled). For the remaining two 
haplotypes with frequency >1% (i.e., RV and WT), 
dominant and recessive genetic models were assumed 
respectively (i.e., for RV, RV haplotype carriers – 
defined as rs2070325 = A and rs11699009 = T on at 
least one chromosome – vs. non-carriers; and for WT, 
WT homozygotes – defined as rs2070325 = A and 
rs11699009 = C on both chromosomes – vs. WT 
heterozygotes – defined as rs2070325 = A and 
rs11699009 = C on one chromosome – plus remaining 
haplotype alleles pooled, respectively).  
Haplotype frequencies and phases were estimated 
from the observed genotypes. Fisher's Exact test were 
used for the comparison of frequencies of analyzed 
haplotypes. In order to evaluate if the detected effects 
of the analyzed polymorphisms on frailty status might 
finally result in differential patterns of survival of the 
different relevant genotypes, the survival after  
11 years from the baseline visit was estimated. 
Kaplan–Meier survival curves were estimated for 
carriers vs non carriers of the relevant haplotype; in 
order to evaluate their predictive value with respect to 
mortality risk, the obtained survival curves were then 
compared by log-rank test. Hazard Ratios (HR) and 
95% Confidence Intervals (95% CI) were estimated 
by using Cox proportional hazard models taking also 
into account possible confounder variables (age, 
gender, frailty status). Subjects alive after the follow-
up time were considered as censored, and this time 
was used as the censoring date in the survival 
analyses. All the analyses were performed in R 
environment [36] and SPSS 25.0 (SPSS Inc., Chicago, 
IL). A significance level (α) of 0.05 was chosen in all 
the tests. 
 
Animal study 
Generalized linear mixed model analysis (SPSS 25.0) 
was used to take into account the longitudinal design 
of the study in mice. The identifier of each mouse, age 
group, gender, age of mouse at inclusion and time was 
indicated in the model. The linear model was 
developed assuming normal distribution with identity 
link function for data of the Clinical Frailty Index. 
The Satterthwaite approximation and robust estimator 
were used to take into account unbalanced data and 
violation of the assumptions. Fisher exact test was 
used to compare the prevalence of the physical frailty 
phenotype between control and treated animals. 
Differential patterns of survival due to the treatment 
were estimated by Cox-regression taking also into 
account possible confounder variables (age, age group 
and gender). 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Figure 
 
 
 
Supplementary Figure 1. Schematic of the study design adopted*. * The age of the mice refers to the range of age at the beginning of 
the indicated month from the inclusion. 
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Supplementary Tables 
 
Supplementary Table 1. Prevalence of physical frailty (Fried’s phenotype) in treated and control mice at the  
3rd month (before treatment) and at the 7th month (after treatment) from the inclusion in the study*. 
Age of mice at the 
beginning of the 
study 
Status 
Month 3 
(Before treatment) 
Month 7 
(Post treatment) 
Control LAV-BPIFB4 Control LAV-BPIFB4 
Adult mice Frail 2 (8.3%) 1 (4.5%) 2 (9.5%) 1 (4.8%) Non-frail 22 (91.7%) 21 (95.5%) 19 (90.5%) 20 (95.2%) 
Old mice Frail 4 (15.4%) 3 (10.7%) 8 (44.4%) 5 (20%) Non-frail 22 (84.6%) 25 (89.3%) 10 (55.6%) 20 (80%) 
*Data are reported as number of mice (%). At month 3: p = 0.741 by Fisher’s exact test; At month 7: p = 0.170 by Fisher’s 
exact test; The reduced number of mice at month 7 is due to death events occurring during the study. 
 
Please browse Full Text version to see the data of Supplementary Table 2. 
 
Supplementary Table 2. Number of mice (%) with frailty scores of 0, 0.5 or 1.0 for each parameter used to develop 
the frailty index. 
 
Supplementary Table 3. Measurement performed to define Physical Frailty phenotype*. 
Criterion Shrinking Weakness Endurance Slowness Activity 
Measurement 1 Current weight 
Grip strength 
meter 
Treadmill 
distance 
Highest speed interval that the 
mouse traveled for at least 3 s 
in an open field test (5 min) 
% the mice walked 
or run in a 5-min 
open field test 
Measurement 2 Weight loss in 1 month 
Dynamometer 
force 
Mean time at 
Rotarod test Mean stride length 
Total distance run by 
the mouse in a 5-min 
open field test 
Measurement 3 Weight loss in 2 month 
Increasing 
weights lift test 
Increasing 
weights lift test Max speed at rotarod test - 
*For each criterion a composite Z-score was derived as the mean of the Z-scores from each measurement. Mice that fell in 
the bottom 20% of our cohort for the composite score computed for each criterion (Shrinking, Weakness, Endurance, 
Slowness and Activity), were assigned one point. The mice were considered as frail when they reached 3 or more points on a 
maximum of 5.  
 
